Hemophilia Management

Introduction

If you or your child has been diagnosed with hemophilia, you are likely thinking about what daily life will look like, how bleeding episodes are prevented and treated, and how to protect long-term health — especially the joints. Hemophilia is a lifelong inherited bleeding disorder, but the way it is managed has changed significantly over the last two decades. Many people with hemophilia today go to school, work, travel, and stay physically active with the support of regular treatment and a specialist care team.

This guide walks through what hemophilia is, how it is diagnosed, the modern options for managing it, what to expect from ongoing care, and how to think about life with the condition over the long term. It is written for adults with hemophilia, for parents of children with hemophilia, and for family members who want to understand the condition better. The information here is general; the specific plan for any one person is decided together with a hematologist who knows the patient’s history.

What Is Hemophilia?

Hemophilia is a bleeding disorder in which the blood does not clot properly because one of the clotting factors is missing or present in reduced amounts. Clotting factors are proteins that work together in a chain reaction to stop bleeding after an injury. When one factor in the chain is low, the body still tries to form a clot, but the clot is weaker, slower, and less stable than usual.

The result is not that bleeding is faster — it is that bleeding lasts longer, and that internal bleeding can occur even without a clear injury. Joints and muscles are particularly affected because small bleeds inside them can build up over time and cause lasting damage if not treated.

Hemophilia is most commonly inherited. It is not contagious. It is not caused by anything the person did, anything the parents did during pregnancy, or by diet or lifestyle.

Types of Hemophilia

Hemophilia is classified by which clotting factor is affected and by how severe the deficiency is.

Hemophilia A

Hemophilia A is caused by a reduced level of clotting factor VIII (8). It is the most common type, accounting for the large majority of cases. It is sometimes called classic hemophilia.

Hemophilia B

Hemophilia B is caused by a reduced level of clotting factor IX (9). It is less common than hemophilia A but is managed using similar principles, with factor IX products in place of factor VIII.

Rare factor deficiencies

Other clotting factor deficiencies exist (for example, factor VII, factor XI, and factor XIII deficiencies) and are sometimes grouped under the broader term “bleeding disorders.” They are much rarer than hemophilia A and B and are managed by hematologists with experience in rare bleeding disorders.

Acquired hemophilia

In rare cases, hemophilia can develop later in life in someone who was not born with it. This is called acquired hemophilia and is caused by the body’s immune system producing antibodies that block its own clotting factor — usually factor VIII. It can appear after pregnancy, alongside autoimmune conditions, with certain cancers, or for no clear reason. Acquired hemophilia is treated differently from inherited hemophilia, with a focus on stopping the antibodies as well as controlling bleeding.

Severity classification

Within hemophilia A and B, severity is described by how much of the clotting factor is present in the blood, compared to normal:

• Severe hemophilia — less than 1% of normal factor activity. Bleeds, including spontaneous bleeds into joints and muscles, are common.
• Moderate hemophilia — 1% to 5% of normal factor activity. Bleeds usually follow minor injury, but spontaneous bleeds can occur.
• Mild hemophilia — 5% to 40% of normal factor activity. Bleeds are usually linked to surgery, dental work, or significant injury and may go unrecognised until one of these events.

Causes and Risk Factors

Hemophilia A and B are caused by changes (mutations) in the genes that carry the instructions for making factor VIII or factor IX. These genes sit on the X chromosome, which is why hemophilia is described as an X-linked condition.

• Hemophilia is far more common in boys and men.
• Girls and women who carry the gene change are often called “carriers.” Some carriers have completely normal clotting; others have lower-than-normal factor levels and can experience bleeding symptoms, sometimes significant ones. Modern guidance increasingly recognises symptomatic carriers as having hemophilia in their own right, rather than only as carriers.
• A girl can have hemophilia in rare situations — for example, when both X chromosomes carry the gene change, or in certain genetic patterns.

About one-third of people with hemophilia have no family history of the condition. In these cases, the gene change has arisen newly in that person or in the mother’s egg cell. The absence of family history does not make the diagnosis any less real, and genetic counselling can help families understand what the diagnosis means for siblings and future children.

Signs and Symptoms

This section is for orientation rather than first-time symptom recognition — if you are reading this, you or your child likely already has the diagnosis or is being investigated for it. Understanding what bleeds look like helps you and your family recognise them early and act quickly, which is one of the most important things you can do to protect long-term health.

Common bleeding patterns

• Easy bruising, including raised or unusually large bruises in young children
• Prolonged bleeding after small cuts, dental work, vaccinations, or surgery
• Frequent or hard-to-stop nosebleeds
• Blood in the urine or stool
• Heavy or prolonged menstrual periods in women and girls with low factor levels

Joint bleeds (hemarthrosis)

Joint bleeds are one of the most important signs to recognise. A joint bleed often starts with a feeling of warmth, tightness, or “bubbling” inside the joint — sometimes called an “aura” — before pain or swelling becomes obvious. The knees, ankles, and elbows are the joints most often affected. Repeated bleeds into the same joint can damage the cartilage and lining over time, leading to a condition called hemophilic arthropathy. Treating a joint bleed as early as possible — ideally at the first sign — is one of the central goals of modern hemophilia care.

Muscle bleeds

Bleeding into a muscle can cause swelling, pain, and stiffness. Bleeds into deeper muscles, such as the iliopsoas (in the hip area) or the calf, can be harder to recognise and may press on nearby nerves or blood vessels.

Serious internal bleeds

Less common but more dangerous bleeds include bleeding into the head (intracranial), the neck and throat, or the abdomen. These need immediate emergency assessment. Head bleeds in particular can occur after relatively minor knocks and may not show outward signs at first.

Diagnosis

Hemophilia is diagnosed through a combination of clinical history, family history, and specific blood tests. Many cases are picked up in childhood — sometimes in newborns with a known family history, sometimes after unusual bruising as a baby starts to crawl and walk, and sometimes after a first bleed following an injury or procedure.

Blood tests

• Activated partial thromboplastin time (aPTT) — a screening test that is typically prolonged in hemophilia A and B.
• Clotting factor assays — measure the activity level of factor VIII and factor IX directly. These confirm the diagnosis and define severity.
• Inhibitor testing (Bethesda assay) — checks whether the body has produced antibodies against clotting factor. This becomes important once treatment has started.
• Other coagulation tests — used to rule out other causes of bleeding, such as von Willebrand disease, which can look similar in some respects.

Genetic testing and family screening

Genetic testing can identify the specific gene change responsible. This information is useful for confirming the diagnosis, for identifying carriers in the family, and for genetic counselling around future pregnancies. Family screening is typically offered to mothers, sisters, and daughters of a person with hemophilia, and is something to discuss with a hematologist or a genetic counsellor.

Treatment and Management

Modern hemophilia management focuses on three goals: preventing bleeds before they happen, treating bleeds quickly when they do happen, and protecting joints and overall health over a lifetime. The treatment plan is highly individualised and depends on the type of hemophilia, its severity, the person’s age and activity level, whether inhibitors are present, and what is available locally. Care is most effective when it is coordinated through a specialist hemophilia team, often called a hemophilia treatment centre, that includes hematologists, nurses, physiotherapists, and other specialists.

Factor replacement therapy

The traditional cornerstone of treatment is replacing the missing clotting factor through an intravenous (into the vein) infusion. Factor concentrates are available as:

• Plasma-derived concentrates — purified from donated human plasma, with multiple steps to remove or inactivate viruses.
• Recombinant concentrates — made through laboratory techniques without using human plasma.
• Extended half-life (EHL) products — engineered to stay in the body longer, reducing how often infusions are needed.

Factor replacement can be used in two ways:

• On-demand treatment — given when a bleed starts, to stop it as early as possible.
• Prophylaxis — regular scheduled infusions to keep factor levels high enough to prevent most bleeds from happening in the first place. The World Federation of Hemophilia recommends prophylaxis as the standard of care for people with severe hemophilia, and increasingly for those with moderate hemophilia who experience bleeds, because of strong evidence that it reduces joint damage and improves long-term function.

Non-factor therapies

A newer group of treatments works without replacing the missing clotting factor. The best established is emicizumab, a subcutaneous (under-the-skin) injection used in hemophilia A. It bridges the gap that factor VIII normally fills in the clotting chain, so the body can still form clots. Advantages described in clinical studies include fewer bleeds, less frequent dosing (weekly, fortnightly, or monthly depending on the regimen), and the avoidance of repeated venous access — which is particularly relevant in young children.

Other non-factor therapies, including treatments aimed at rebalancing the clotting system in different ways, are at various stages of approval and availability. Whether these are an option in any individual case depends on the type and severity of hemophilia, age, and what is approved and available in the country of care.

Management of inhibitors

Some people who receive factor replacement develop inhibitors — antibodies that block the infused factor from working. Inhibitors are one of the most challenging complications of hemophilia treatment, particularly in hemophilia A. They are more common in the first 50 or so exposures to factor concentrate, which is why young children are monitored closely after starting treatment.

When inhibitors develop, the treatment plan changes. Options used by specialist teams include:

• Bypassing agents — products that help the body form clots without needing the blocked factor. Examples include activated prothrombin complex concentrate and recombinant activated factor VII.
• Immune tolerance induction (ITI) — a programme of regular, often high-dose factor infusions over months to years, aimed at retraining the immune system to accept the factor.
• Non-factor therapies such as emicizumab — which work regardless of whether an inhibitor is present and have changed care significantly for many people with inhibitors in hemophilia A.

Inhibitor management requires close oversight by a hematologist experienced in hemophilia.

Gene therapy

Gene therapy aims to give the body the genetic instructions to produce its own clotting factor by delivering a working copy of the gene, usually using a modified, non-disease-causing virus as a carrier. Several gene therapy products have been approved for adults with hemophilia A or hemophilia B in some countries. Clinical study data have shown that many treated patients have substantially higher factor levels for years after a single infusion, with reduced or eliminated need for regular factor or non-factor treatment in some.

Important considerations include eligibility (current approvals are for adults, and not for people with active inhibitors or certain antibodies to the carrier virus), the need for liver monitoring after treatment, the durability of the response (which varies and continues to be studied), and local availability. Whether gene therapy is an option for any individual is a detailed discussion with a hematologist familiar with the current evidence.

Supportive medications and treatments for bleeds

• Desmopressin (DDAVP) — can raise factor VIII levels temporarily and is used for some people with mild hemophilia A. It is not effective for hemophilia B.
• Antifibrinolytic medications — such as tranexamic acid, useful for mouth, nose, and menstrual bleeding by stabilising clots that have already formed.
• Local measures — rest, ice, compression, and elevation for joint bleeds, alongside specific factor or non-factor treatment.
• Pain control — using medications that do not interfere with platelet function. Aspirin and most non-steroidal anti-inflammatory drugs (NSAIDs) are typically avoided because they can worsen bleeding; pain medication choices should be guided by the hematology team.

Orthopaedic and physiotherapy care

Joint health is central to long-term outcomes in hemophilia. Specialist physiotherapy helps maintain muscle strength and joint range of motion, supports recovery after bleeds, and reduces the likelihood of further bleeds. For joints already damaged by repeated bleeds, options range from joint injections to, in some cases, joint replacement surgery, always carried out with careful planning around clotting factor cover.

Lifestyle and Self-Management

Day-to-day choices play a meaningful role in living well with hemophilia. Self-management is taught and supported by the hemophilia treatment team and adapted over time.

Physical activity

Regular physical activity is encouraged. Strong muscles protect joints, healthy weight reduces joint stress, and exercise supports overall wellbeing. Activities are usually chosen by their level of contact and impact:

• Generally encouraged: swimming, walking, cycling on safe routes, table tennis, golf, and similar low-impact activities.
• Approached with care: running, certain team sports, and gym work, often with individual planning by a physiotherapist.
• Generally avoided: high-contact and high-impact sports such as boxing, rugby, and tackle football, because of the risk of head, joint, and internal injuries.

The right balance depends on severity, treatment regimen, and individual goals, and is something to plan together with the care team.

Injury prevention at home

• Padding sharp corners for young children learning to walk
• Using helmets and protective equipment for cycling, skating, and similar activities
• Good footwear and care with stairs as adults age
• Avoiding intramuscular injections where possible; many vaccines can be given subcutaneously or with pressure techniques arranged by the team

Diet and weight

A balanced diet supports general health. Maintaining a healthy weight is particularly important because excess weight increases load on joints already at risk from past bleeds. Adequate calcium and vitamin D support bone health, which can be affected over time in hemophilia.

Dental care

Regular dental check-ups help prevent gum disease and the need for procedures that may cause bleeding. Dental work should be planned with the hematology team so that any necessary factor or supportive treatment is arranged in advance.

Travel and identification

Carrying a medical identification card or wearing a medical alert bracelet helps in an emergency. When travelling, it is helpful to carry a treatment summary, a letter from the hemophilia team, and supplies of factor or other treatments along with documentation needed at borders. Many hemophilia centres can also help identify a treatment centre at the destination in case of need.

Monitoring and Follow-up

People with hemophilia benefit from regular review at a hemophilia treatment centre. Ongoing monitoring usually includes:

• Reviewing bleed history, including any joint or muscle bleeds, and adjusting treatment if bleeds are occurring on the current plan
• Checking factor levels and, in those receiving factor replacement, monitoring for inhibitors
• Joint assessment by physiotherapy, sometimes with imaging such as ultrasound or MRI
• Reviewing growth and development in children
• Mental health and psychosocial support, which is recognised as a key part of comprehensive care
• Updating vaccinations, including hepatitis A and B, with adjustments for injection technique
• Discussing new treatment options as they become available, such as extended half-life products, non-factor therapies, and gene therapy

With modern care many complications can be reduced or delayed, but they remain important to understand.

Joint damage (hemophilic arthropathy)

Repeated bleeds into the same joint cause progressive damage to the cartilage and joint lining, leading to pain, stiffness, and reduced range of motion. Prophylaxis and early treatment of bleeds are the main strategies to prevent or slow this. Once joint damage is established, physiotherapy, pain management, and in some cases orthopaedic surgery may be needed.

Inhibitors

As described above, inhibitors are one of the most significant complications of factor replacement therapy and change the treatment approach.

Bleeding emergencies

Head injuries, severe abdominal pain, neck swelling, and certain other situations need urgent assessment with rapid factor or alternative treatment, even before imaging in some cases.

Infection risk from blood products

Older generations of plasma-derived products carried a risk of transmitting blood-borne viruses, and many older patients live with the consequences of past infections. Modern viral inactivation steps and recombinant products have made this risk very small for current treatments, but routine monitoring for hepatitis and HIV is part of long-term care.

Psychological and social impact

Living with a chronic bleeding disorder can affect mental health, school and work attendance, relationships, and family planning. Mental health support, peer connections through patient organisations, and counselling are recognised as part of comprehensive care.

Living with Hemophilia

Most adults with hemophilia today work in a wide range of occupations, have families, travel, and stay active. The shape of daily life depends on severity and treatment plan, but several themes are common.

Work and education

Most types of work are possible. Roles with heavy manual labour, high fall risk, or extensive overhead lifting may need adjustment, especially if joint damage has already developed. Schools and workplaces can usually accommodate appointments and the occasional bleed-related absence; an explanatory letter from the hemophilia team can help.

Relationships and family planning

Genetic counselling helps individuals and couples understand the chance of passing hemophilia on and the options available, including prenatal diagnosis. Female carriers can have their own factor levels measured and a personal bleeding plan made, which is particularly important around pregnancy, childbirth, and surgery.

Pregnancy and childbirth in carriers

Women who carry the hemophilia gene need a planned pregnancy and delivery, with attention to the mother’s factor levels and to safe delivery practices for a potentially affected baby. This is coordinated between obstetrics and hematology.

Emotional wellbeing

Anxiety around bleeds, frustration with treatment routines, and the impact on family life are common experiences. Counselling, peer support through hemophilia societies, and connection with other families can be valuable parts of management.

Hemophilia in Children

For parents, hemophilia in childhood brings its own set of questions and decisions. Care has changed dramatically; outcomes for children diagnosed and treated today are very different from those of past generations.

Diagnosis in infancy

Babies with a known family history are often tested at or shortly after birth, with cord blood sampling and follow-up factor assays. When there is no family history, the diagnosis may come after unexpected bruising as the baby becomes mobile, prolonged bleeding from a circumcision or heel-prick site, or bleeding into the mouth as teeth come in.

Starting prophylaxis

For children with severe hemophilia, the World Federation of Hemophilia recommends starting prophylaxis early — typically in the first one to two years of life, before significant joint bleeds have occurred. The aim is to protect joints from the very start. Prophylaxis may involve regular factor infusions or, for hemophilia A, subcutaneous non-factor therapy such as emicizumab. The choice depends on availability, the family’s circumstances, and the medical plan.

Venous access in young children

Repeated intravenous access can be difficult in small children. Options that the hemophilia team may discuss include peripheral venous access with the help of a trained nurse, a central venous access device (port) in selected cases, and non-factor therapies that are given under the skin rather than into a vein.

School and activities

Most children with hemophilia attend mainstream school. Practical steps include a written care plan for the school, training for school staff on what to do if there is an injury, identifying a contact person, and planning for sports and physical education with the help of a physiotherapist. Active play is encouraged within the limits agreed with the care team; long-term avoidance of all physical activity is not the goal.

Supporting parents and siblings

Parents are usually trained to recognise bleeds early, administer treatment at home, and decide when to call the hemophilia team. Siblings often have questions and feelings of their own; involving them in age-appropriate explanations can help the whole family.

Transition to adult care

Moving from paediatric to adult hemophilia services is a planned process, ideally beginning in early adolescence. It includes building up the young person’s knowledge of their own condition and treatment, learning self-infusion if appropriate, and gradually taking responsibility for appointments and decisions.

Prevention of Progression and Complications

Hemophilia cannot currently be prevented in someone who has inherited the gene change, but the progression of joint damage and other complications can be substantially reduced. Key elements are:

• Prophylaxis where indicated, with the aim of preventing bleeds rather than only reacting to them
• Treating any bleed as early as possible — ideally at the first warning sign
• Regular physiotherapy and active care of joints
• Avoiding medications that increase bleeding risk unless approved by the hematology team
• Up-to-date vaccinations against hepatitis A and B
• Regular follow-up at a hemophilia treatment centre

When to Seek Urgent Care

Some situations need urgent medical assessment, often with factor or alternative treatment given before detailed investigations. People with hemophilia and their families are usually trained by their hemophilia centre to recognise these. They include:

• Any head injury, even if it seems mild, and any new severe or persistent headache, vomiting, drowsiness, or confusion
• Bleeding into the neck, throat, or mouth that could affect breathing
• Severe abdominal or back pain, which can indicate internal bleeding
• A bleed into a joint or muscle that is not improving with usual home treatment
• Numbness, tingling, or weakness in a limb after a muscle bleed, which can suggest pressure on a nerve
• Heavy or prolonged bleeding from any site that does not stop with usual measures

If in doubt, it is usually better to contact the hemophilia treatment centre or attend an emergency department early. A treatment card or letter from the hemophilia team helps emergency staff give the right care quickly.

Frequently Asked Questions

Is hemophilia curable?

Hemophilia is not yet considered curable in the traditional sense. Gene therapy has changed the outlook for some adults with hemophilia A or B by raising factor levels for years after a single treatment, but it is not suitable for everyone and long-term durability continues to be studied. For most people, hemophilia is managed as a lifelong condition with treatments that allow a full and active life.

Can people with hemophilia live a normal life?

Yes — with appropriate care, most people with hemophilia today go to school, work, have relationships, and stay active. Severity, treatment plan, and access to specialist care all influence what daily life looks like.

Can hemophilia treatment be done at home?

Home treatment is a standard part of modern hemophilia care for many patients and families. People are trained by their hemophilia centre to give factor infusions or non-factor injections at home, recognise bleeds, and know when to seek additional help. Home treatment allows bleeds to be treated faster, which protects joints over time.

Does hemophilia get worse with age?

Hemophilia itself does not change in severity over a lifetime — factor levels generally stay stable. However, the effects of past joint bleeds can accumulate, so joint care and physiotherapy become more important with age. People who have been on effective prophylaxis from early childhood typically have far less joint damage than earlier generations.

Can women have hemophilia?

Yes. Women and girls can have hemophilia, particularly in certain genetic patterns or when both X chromosomes carry the gene change. Many female carriers also have lower-than-normal factor levels and bleeding symptoms, and modern guidance recognises symptomatic carriers as having hemophilia in their own right.

Is hemophilia contagious?

No. Hemophilia is an inherited condition. It cannot be passed from person to person through contact, blood, saliva, or any other route.

What sports are safe?

Low-impact, non-contact activities such as swimming, walking, cycling, and table tennis are generally encouraged. High-contact sports such as boxing, rugby, and tackle football are usually avoided because of the risk of significant bleeds. Many sports in between can be considered with planning, protective equipment, and physiotherapy guidance. Decisions are individual and made together with the care team.

How is dental work managed?

Most dental work, including extractions, can be done safely with planning. The hematology team and dentist coordinate on factor cover or non-factor support, antifibrinolytic medications such as tranexamic acid, and local measures. Routine preventive dental care reduces the need for invasive procedures.

Will my child pass hemophilia on to their children?

The inheritance pattern depends on whether the affected parent is male or female. Genetic counselling is the best way to understand the chances for any individual family, and to learn about options such as prenatal testing if relevant.

Conclusion

Hemophilia is a lifelong inherited bleeding disorder, but it is one of the conditions in which modern care has made the largest difference. Factor replacement, non-factor therapies, prophylaxis, gene therapy, and comprehensive multidisciplinary care have together changed what life with hemophilia looks like — particularly for children diagnosed today, who can grow up with their joints largely protected and with a wide range of life choices open to them.

Day-to-day life with hemophilia is built on a few core habits: knowing your own bleeding pattern, treating bleeds early, staying active in ways suited to your body, keeping in regular contact with a specialist team, and reaching out promptly when something does not seem right. With these in place, hemophilia becomes a condition that is managed alongside the rest of life, rather than one that defines it.